학력

• 2007.02

  한양대학교 의과대학 의학사

• 2012.02

  성균관대학교 의과대학 의학석사

주요경력

• 2022.03 ~ 현재

  인하대병원 혈액종양내과 부교수

• 2023.08 ~ 2023.12

  호스피스완화의료센터장

• 2018.01 ~ 2022.02

  인하대병원 혈액종양내과 조교수

• 2016.01 ~ 2018.01

  인하대병원 혈액종양내과 임상강사

• 2015.01 ~ 2016.01

  삼성서울병원 혈액종양내과 임상강사

• 2012.01 ~ 2015.01

  대한민국 육군 군의장교 (대위)

• 2008.01 ~ 2012.01

  삼성서울병원 내과 전공의

• 2007.01 ~ 2008.01

  한양대학교 의료원 수련의

학회활동

• -

  대한혈액학회 정회원

• -

  한국임상암학회 정회원

• -

  대한암학회 정회원

수상경력

주요 논문 및 저서

• 2018

  Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, et al. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer research and treatment : official journal of Korean Cancer Association. 2018.

• 2018

  Kim J, Cho J, Lee MH, Lim JH. Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. Scientific reports. 2018;8(1):11738.

• 2018

  Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018:Jco2017773184.

• 2018

  Kim EK, Cho J, Kim JY, Chang SA, Park SJ, Choi JO, et al. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data. Cancer research and treatment : official journal of Korean Cancer Association. 2018.

• 2018

  Cho J, Kim SJ, Park S, Yoo KH, Ki CS, Ko Y, et al. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma. Ann Hematol. 2018.

• 2018

  Park M, Kim M, Park J, Cho J. Life-Threatening Thrombocytopenia Following Intravenous Contrast Media Infusion. Yonsei Med J. 2018;59(1):158-61.

• 2018

  Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, et al. Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma. Clin Transl Oncol. 2017;19(10):1247-52

• 2017

  Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, et al. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol. 2017;28(9):2199-205.

• 2016

  Kim HK, Ham JS, Byeon S, Yoo KH, Jung KS, Song HN, et al. Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. Cancer research and treatment : official journal of Korean Cancer Association. 2016;48(4):1382-8.

• 2016

  Kim HK, Lee S, Kim K, Heo MH, Lee H, Cho J, et al. Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Transl Oncol. 2016;9(6):557-64.

• 2016

  Lee JY, Lee I, Chang WJ, Ahn SM, Lim SH, Kim HS, et al. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget. 2016;7(28):43492-503.

• 2016

  Cho J, Ahn S, Yoo KH, Kim JH, Choi SH, Jang KT, et al. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Invest New Drugs. 2016;34(6):677-84.

• 2016

  Cho J, Lee J, Kim J, Kim ST, Lee S, Kim SY, et al. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Transl Oncol. 2016;9(5):466-71.

• 2016

  Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, et al. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. J Thorac Oncol. 2016;11(4):e45-7.

• 2013

  Cho JH, Kim NJ, Ko SM, Kim C, Ahn HK, Yun J, et al. A case report of paraneoplastic pemphigus associated with esophageal squamous cell carcinoma. Cancer research and treatment : official journal of Korean Cancer Association. 2013;45(1):70-3.

• 2012

  Jung HA, Park S, Cho JH, Kim S, Ko YH, Kim SJ, et al. Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study. Ann Hematol. 2012;91(11):1747-56.

• 2010

  Park S, Lee J, Park SH, Park JO, Kang WK, Park YS, et al. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma. Chemotherapy. 2010;56(6):485-91.

• 2008

  Cho JH, Kim KM, Kwon M, Kim JH, Lee J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs. 2012;30(5):2008-14.

언론보도